Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pazopanib plus Anastrozole in Stage II-III ER+ Breast Cancer
NCT01394211Phase 2Terminated
- Sponsor
- University of Arizona
- Start
- Jul 2011
- Primary completion
- Apr 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pazopanib in breast cancer, sponsored by University of Arizona. Primary endpoint: Pathologic Complete Response Rate at 6 months. Started Jul 2011; status: terminated.
02
Drugs
pazopanib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT01394211.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01394211.